Login to Your Account


'A GREAT OUTCOME'

Arbor Pharmaceuticals LLC, of Atlanta, has moved to buy Xenoport Inc. for $467 million in cash, adding the restless leg and postherpetic neuralgia drug Horizant to its neurology portfolio.

more »


Our Habitat for All Things Science
Efficacy comes to phase I cancer trials

Findings that precision medicine benefits patients even in phase I trials, and patients treated with Keytruda (pembrolizumab, Merck & Co. Inc.) had a three-year survival rate of about 40 percent, were among the highlights of the sprawling treasure trove that is the American Society of Clinical Oncology's (ASCO) annual meeting abstracts. Abstracts for the 2016 annual meeting, which will be held in Chicago June 3-7, were publicly released yesterday.

READ MORE »

Opinion


Partners in Focus